81 related articles for article (PubMed ID: 26946048)
21. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
[TBL] [Abstract][Full Text] [Related]
22. Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment.
Thornton K; Deming P; Manch RA; Moore A; Kohli A; Gish R; Sussman NL; Khaderi S; Scott J; Mera J; Box T; Qualls C; Sedillo M; Arora S
Hepatol Int; 2016 Jul; 10(4):624-31. PubMed ID: 27098355
[TBL] [Abstract][Full Text] [Related]
23. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections.
Oliviero B; Cerino A; Varchetta S; Paudice E; Pai S; Ludovisi S; Zaramella M; Michelone G; Pugnale P; Negro F; Barnaba V; Mondelli MU
J Hepatol; 2011 Jul; 55(1):53-60. PubMed ID: 21145853
[TBL] [Abstract][Full Text] [Related]
24. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy.
Tsuda N; Yuki N; Mochizuki K; Nagaoka T; Yamashiro M; Omura M; Hikiji K; Kato M
J Med Virol; 2004 Nov; 74(3):406-13. PubMed ID: 15368524
[TBL] [Abstract][Full Text] [Related]
25. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
26. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
Campos-Varela I; Castells L; Esteban JI; Bes M; Rodríguez-Frías F; Sapisochin G; Allende H; Charco R; Esteban R
Transplantation; 2012 Feb; 93(4):450-3. PubMed ID: 22262129
[TBL] [Abstract][Full Text] [Related]
27. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
Martinot-Peignoux M; Stern C; Maylin S; Ripault MP; Boyer N; Leclere L; Castelnau C; Giuily N; El Ray A; Cardoso AC; Moucari R; Asselah T; Marcellin P
Hepatology; 2010 Apr; 51(4):1122-6. PubMed ID: 20069649
[TBL] [Abstract][Full Text] [Related]
28. Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C.
Inokuchi M; Ito T; Uchikoshi M; Shimozuma Y; Morikawa K; Nozawa H; Shimazaki T; Hiroishi K; Miyakawa Y; Imawari M
J Med Virol; 2009 Apr; 81(4):619-27. PubMed ID: 19235854
[TBL] [Abstract][Full Text] [Related]
29. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.
Chuang JY; Yang SS; Lu YT; Hsieh YY; Chen CY; Chang SC; Chang CS; Yeh HZ; Kao JH
Dig Liver Dis; 2009 Jun; 41(6):424-30. PubMed ID: 19004675
[TBL] [Abstract][Full Text] [Related]
30. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C.
Mrani S; Chemin I; Menouar K; Guillaud O; Pradat P; Borghi G; Trabaud MA; Chevallier P; Chevallier M; Zoulim F; Trépo C
J Med Virol; 2007 Aug; 79(8):1075-81. PubMed ID: 17596829
[TBL] [Abstract][Full Text] [Related]
31. Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C.
Hengst J; Falk CS; Schlaphoff V; Deterding K; Manns MP; Cornberg M; Wedemeyer H
J Infect Dis; 2016 Dec; 214(12):1965-1974. PubMed ID: 27683821
[TBL] [Abstract][Full Text] [Related]
32. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis.
Meissner EG; Kohli A; Virtaneva K; Sturdevant D; Martens C; Porcella SF; McHutchison JG; Masur H; Kottilil S
J Viral Hepat; 2016 Jul; 23(7):496-505. PubMed ID: 26840694
[TBL] [Abstract][Full Text] [Related]
33. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.
Murdaca G; Contini P; Cagnati P; Marenco S; Pieri G; Lantieri F; Picciotto A; Puppo F
Clin Exp Med; 2017 Feb; 17(1):93-100. PubMed ID: 26567007
[TBL] [Abstract][Full Text] [Related]
34. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases.
Georgiadou SP; Zachou K; Rigopoulou E; Liaskos C; Mina P; Gerovasilis F; Makri E; Dalekos GN
J Viral Hepat; 2004 Jul; 11(4):358-65. PubMed ID: 15230859
[TBL] [Abstract][Full Text] [Related]
35. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
36. Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection.
Squadrito G; Orlando ME; Pollicino T; Raffa G; Restuccia T; Cacciola I; Di Marco V; Picciotto A; Colucci G; Craxì A; Raimondo G
Am J Gastroenterol; 2002 Jun; 97(6):1518-23. PubMed ID: 12094876
[TBL] [Abstract][Full Text] [Related]
37. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
[TBL] [Abstract][Full Text] [Related]
38. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
[TBL] [Abstract][Full Text] [Related]
39. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
[TBL] [Abstract][Full Text] [Related]
40. Analysis of B-lymphocyte differentiation in patients infected with hepatitis C virus.
Fournillier A; Freida D; Defrance T; Merle P; Trépo C; Inchauspé G
J Med Virol; 2004 Apr; 72(4):566-74. PubMed ID: 14981759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
